Saad Z. Usmani
YOU?
Author Swipe
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials Open
View article: Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Open
View article: Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Data from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Purpose:Lenalidomide (Len) maintenance is the most frequently utilized approach for newly diagnosed patients with multiple myeloma following induction therapy with/without consolidative high-dose melphalan and autologous stem cell transpla…
View article: Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data2 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Trial protocol
View article: Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance
Supplementary Data1 from Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance Open
Revised supplement
View article: Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma Open
View article: Mileage matters: long-distance performance of CARs in multiple myeloma
Mileage matters: long-distance performance of CARs in multiple myeloma Open
Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published …
View article: Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel Open
Non-ICANS neurotoxicities (NINTs) are serious, atypical toxicities associated with ciltacabtagene autoleucel, a commercial chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory multiple myeloma. Risk factors contr…
View article: Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies Open
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID…
View article: Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies Open
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Coh…
View article: A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant Open
What were the results?
View article: SUN-304 Associations of BMI Changes and Adipokines with Survival and Treatment Response During Myeloma Induction Therapy
SUN-304 Associations of BMI Changes and Adipokines with Survival and Treatment Response During Myeloma Induction Therapy Open
Disclosure: R. Thirugnanasambandam: None. R. Firestoe: None. A. Derkach: None. T. Shekarkhand: None. C. Rueda: None. K. Maclachlan: None. M.L. Hultcrantz: None. S. Mailankody: None. D. Patel: None. H. Landau: None. G. Shah: None. M. Scordo…
View article: Data from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Data from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies Open
Ionizing radiotherapy (RT) is a widely used treatment strategy for malignancies. In solid tumors, RT-induced double-strand breaks lead to the accumulation of insertion-deletions (indels; ID), and their repair by nonhomologous end joining h…
View article: Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Supplementary Tables S1-S16 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies Open
Table S1: Demographic Data. Table S2: Exposure History LBCL. Table S3: Exposure History Myeloma. Tables S4: Exposure History for t-MN from PMID: 36626250. Table S5: ID83 Mutational Signatures Contribution for the Patient-Level Lymphoid Coh…
View article: Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies
Supplementary Figures S1-S13 from Mutagenic Impact and Evolutionary Influence of Chemoradiotherapy in Hematologic Malignancies Open
Figure S1: Overview of the Single-Cell Expansion Model. Figure S2: Mutational Profiles of Chemoradiotherapy-Treated Lymphoid Patients. Figure S3: ID83 signature relationships to SBS96 signatures in newly diagnosed MM and BCL. Figure S4: ID…
View article: Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma Open
Circulating tumor cells (CTCs) have emerged as a key prognostic factor in newly diagnosed multiple myeloma (NDMM). However, it remains unclear if high CTC counts represent a mere surrogate of tumor burden or might reflect a distinct genomi…
View article: Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States
Racial differences in the proportion of myeloma cases attributable to excess body weight and diabetes mellitus in the United States Open
Not available.
View article: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma Open
View article: Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15)
Ibrutinib in Combination with Lenalidomide Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (AFT-15) Open
Background: Studies have suggested a synergism between lenalidomide (LEN) and ibrutinib (IBR) in multiple myeloma (MM). Both downregulate IRF4, a key target and master transcriptional factor regulating myeloma cell survival. Method: A 3 + …
View article: Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies Open
View article: Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma Open
The treatment of newly diagnosed multiple myeloma (NDMM) has advanced rapidly in recent years, with the standard of care (SOC) now including not only triplet combinations of proteasome inhibitors (PIs), immunomodulatory agents, and steroid…
View article: AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data
AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data Open
Motivation Efforts to address health disparities are often limited by the lack of robust computational tools for inferring genetic ancestry by calculating an individual’s genetic similarity to continental groups. We have already shown that…
View article: Phylogenetic taxonomy of the Zambian Anopheles coustani group using a mitogenomics approach
Phylogenetic taxonomy of the Zambian Anopheles coustani group using a mitogenomics approach Open
These findings demonstrate the value of mitochondrial genomes in differentiating cryptic taxa and help to confirm morphological identities of An. coustani sensu stricto, Anopheles paludis, Anopheles zeimanni and Anopheles tenebrosus. Diver…
View article: Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience
Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience Open
View article: Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes Open
View article: Data from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Data from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential Open
Purpose:We designed mathematical models to describe and quantify the mechanisms and dynamics of minimal residual disease (MRD) in order to better understand these MRD dynamics; inform future treatment design, including when to stop or chan…
View article: Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Open
CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and s…